Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 351

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Catherine Diefenbach, MD, Brad S. Kahl, MD, Lalita Banerjee, FRCPath, Andrew K McMillan, FRCP, Fiona Miall, MD FRCPath, MRCP, BMBS, Javier Briones, MD PhD, Raul Cordoba, MD PhD, Jamie Hirata, PharmD, YiMeng Chang, MSc, Lisa Musick, PharmD, Pau Abrisqueta, MD PhD

Blood (2019) 134 (Supplement_1): 126.

https://doi.org/10.1182/blood-2019-123669

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Blood (2019) 134 (Supplement_1): 565.

https://doi.org/10.1182/blood-2019-124994

Published: 2019

Journal Articles

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Kiran Naqvi, MDMPH, Yesid Alvarado, MD, Tapan M. Kadia, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Naveen Pemmaraju, MD, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Montalban Bravo, MD

Blood (2019) 134 (Supplement_1): 1726.

https://doi.org/10.1182/blood-2019-126005

Published: 2019

Journal Articles

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Alix E. Seif, MD, Yimei Li, PhD, Viviane C. Cahen, Yuan-Shung V. Huang, MS, Matt Hall, PhD, E. Anders Kolb, MD, Brian T. Fisher, DO, MSCE, Richard Aplenc, MD PhD, Kelly D Getz

Blood (2019) 134 (Supplement_1): 3496.

https://doi.org/10.1182/blood-2019-122887

Published: 2019

Journal Articles

Direct Visualization of Circulating Neutrophil Extracellular Traps Using Cell Fluorescence during Human Septic Shock-Induced Disseminated Intravascular Coagulation

Laure Stiel, MD, Caroline Mayeur-Rousse, MD, Julie Helms, Fehrat Meziani, Laurent Mauvieux, MD PhD

Blood (2019) 134 (Supplement_1): 3583.

https://doi.org/10.1182/blood-2019-124698

Published: 2019

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Jeanne Mendell, PhD MPH, Ruth Namuyinga, MD MPH, Hoang Pham, PharmD, Nabil Said, MD MPH, Yibin Wang, PhD, Tsvetomir Mitov, MD, Ben Kim, PharmD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 1372.

https://doi.org/10.1182/blood-2019-121762

Published: 2019

Journal Articles

Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection

Beth Savage, MSN, ANP, Peter D Cole, MD, Charlotte Thomas-Hawkins, PhD RN, Jerod Stapleton, PhD, Pamela de Cordova, PhD RN-BC, Linda Flynn, PhD RN, FAAN

Blood (2019) 134 (Supplement_1): 1327.

https://doi.org/10.1182/blood-2019-123534

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Carbapenemase-Producing Enterobacteriaceae (CPE) Bloodstream Infections (BSI) in Neutropenic Patients (pts) with Acute Leukemia (AL). Comparison of 2 Strategies

Marcos Lemos, MD, Rebeca Brito, MD, Margarida Fevereiro, MD, Mariana L. Fernandes, MD, Filipa Saraiva, MD, Susana G Pereira, MD, Leonor Sarmento, MD, Alexandra Monteiro, MD, Aida B Sousa, MD

Blood (2019) 134 (Supplement_1): 1333.

https://doi.org/10.1182/blood-2019-124986

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Herve Ghesquieres, MD PhD, Olivier Casasnovas, MD, Emmanuelle Nicolas-Virelizier, MD, Damaj Gandhi Laurent, MD PhD, Vincent Delwail, MD, Mohamed Touati, MD, Katell Le Du, MD, Franck Morschhauser, MD PhD, Christophe Bonnet, MD, Agathe Waultier-Rascalou, MD, Frederique Orsini-Piocelle, MD, Marc André, Myriam Ben Boutieb, Fabienne Morand, Diane Damotte, MD PhD, Alexandra Traverse-Glehen, MD PhD, Philippe Quittet, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 2832.

https://doi.org/10.1182/blood-2019-129016

Published: 2019

Journal Articles

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

Pierre-Edouard Debureaux, Flore Sicre de Fontbrune, Carmem M. S. Bonfim, MD, Jean-Hugues Dalle, MD PhD, Nimrod Buchbinder, MD, Yves Bertrand, MD, Cecile Renard, MD, Edouard Forcade, MD, Juliana Fernandes, MD, Alexis Talbot, MD, Ricardo Pasquini, MD, Jean Soulier, MD PhD, Thierry Leblanc, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2498.

https://doi.org/10.1182/blood-2019-122007

Published: 2019

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Blood (2019) 134 (Supplement_1): 3876.

https://doi.org/10.1182/blood-2019-131123

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

NARROW

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)

Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS)

Direct Visualization of Circulating Neutrophil Extracellular Traps Using Cell Fluorescence during Human Septic Shock-Induced Disseminated Intravascular Coagulation

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Hispanic Race Is Associated with Increased Risk of Severe Sepsis in 1913 Hospitalizations of Children with AML and Infection

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Carbapenemase-Producing Enterobacteriaceae (CPE) Bloodstream Infections (BSI) in Neutropenic Patients (pts) with Acute Leukemia (AL). Comparison of 2 Strategies

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA)

Efficacy and Safety of a FLAG-Sequential Regimen Followed By Hematopoietic Stem Cell Transplantation for Myelodysplasia or Acute Leukemia in Fanconi Anemia: A Franco-Brazilian Report

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Tisagenlecleucel (CTL019) in B-Cell Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults: The French Experience

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only